Akari Therapeutics PLC Market Cap ($7.15 Million)
Market Cap & Net Worth: Akari Therapeutics PLC (AKTX)
Akari Therapeutics PLC market cap. Akari Therapeutics PLC (NASDAQ:AKTX) has a market capitalization of $7.15 Million ($7.15 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27726 globally and #5736 in its home market, demonstrating a 6.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Akari Therapeutics PLC's stock price $8.15 by its total outstanding shares 1144588 (1.14 Million). Also see Akari Therapeutics PLC cash conversion from operations for how efficiently the company converts equity into cash flow.
Akari Therapeutics PLC Market Cap History (2015–2026)
Akari Therapeutics PLC market cap history from 2015 to 2026. Data shows change from $331.93 Million to $9.33 Million (-29.22% CAGR). Check Akari Therapeutics PLC stock price for real-time trading data and today's change.
Index Memberships
Akari Therapeutics PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #789 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2543 of 3165 |
Weight: Akari Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Akari Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Akari Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AKTX shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AKTX by Market Capitalization
Companies near Akari Therapeutics PLC in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Akari Therapeutics PLC for a full breakdown of the balance sheet.
Key companies related to Akari Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Akari Therapeutics PLC (2015–2026)
Market capitalization of Akari Therapeutics PLC from 2015 to today. Between 2015 and today, Akari Therapeutics PLC's market cap moved from $331.93 Million to $ 9.33 Million, with a yearly change of -29.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.33 Million | +2720.24% |
| 2025 | $330.79K | -76.31% |
| 2024 | $1.40 Million | -60.90% |
| 2023 | $3.57 Million | -66.80% |
| 2022 | $10.76 Million | -68.67% |
| 2021 | $34.34 Million | -18.92% |
| 2020 | $42.35 Million | +5.71% |
| 2019 | $40.06 Million | +11.46% |
| 2018 | $35.94 Million | -63.74% |
| 2017 | $99.12 Million | -38.49% |
| 2016 | $161.16 Million | -51.45% |
| 2015 | $331.93 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Akari Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.15 Million USD |
| MoneyControl | $7.15 Million USD |
| MarketWatch | $7.15 Million USD |
| marketcap.company | $7.15 Million USD |
| Reuters | $7.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more